Potential role for oral tolerance in gene therapy
| dc.contributor.author | Butterfield, John S.S. | |
| dc.contributor.author | Li, Xin | |
| dc.contributor.author | Arisa, Sreevani | |
| dc.contributor.author | Kwon, Kwang-Chul | |
| dc.contributor.author | Daniell, Henry | |
| dc.contributor.author | Herzog, Roland W. | |
| dc.date.accessioned | 2025-01-13T19:11:19Z | |
| dc.date.available | 2025-01-13T19:11:19Z | |
| dc.date.copyright | 2023-09-01 | |
| dc.date.issued | 2023-09-01 | |
| dc.description.abstract | Oral immunotherapies are being developed for various autoimmune diseases and allergies to suppress immune responses in an antigen-specific manner. Previous studies have shown that anti-drug antibody (inhibitor) formation in protein replacement therapy for the inherited bleeding disorder hemophilia can be prevented by repeated oral delivery of coagulation factor antigens bioencapsulated in transplastomic lettuce cells. Here, we find that this approach substantially reduces antibody development against factor VIII in hemophilia A mice treated with adeno-associated viral gene transfer. We propose that the concept of oral tolerance can be applied to prevent immune responses against therapeutic transgene products expressed in gene therapy. © 2023 Elsevier Inc. | |
| dc.identifier.uri | https://repository.upenn.edu/handle/20.500.14332/60753 | |
| dc.publisher | Elsevier | |
| dc.relation.doi | 10.1016/j.cellimm.2023.104742 | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.source.journaltitle | Cellular Immunology | |
| dc.source.volume | 391-392 | |
| dc.subject | Dentistry | |
| dc.subject.other | Gene therapy | |
| dc.subject.other | Hemophilia | |
| dc.subject.other | Oral tolerance | |
| dc.title | Potential role for oral tolerance in gene therapy | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| upenn.schoolDepartmentCenter | School of Dental Medicine::Departmental Papers (Dental) |